The Coffee That Pays You Back!

Fine out more information about Ganoderma in our Coffee's and Tea's at www.americashealthiercoffee.com
Showing posts with label Drugs. Show all posts
Showing posts with label Drugs. Show all posts

Tuesday, July 10, 2012

Lowering Cholesterol - Long-term Multiple Drugs Effective

Editor's Choice
Main Category: Cholesterol
Also Included In: Statins;  Cardiovascular / Cardiology
Article Date: 29 Jun 2012 - 8:00 PDT Current ratings for:
Lowering Cholesterol - Long-term Multiple Drugs Effective
5 stars5 stars
In a recent study it has been found that cholesterol therapy using multiple drugs over an extended period may be more effective than taking a single statin medication. In previous studies the benefits of using a combination of two or three drugs aimed to aggressively lower LDL (bad cholesterol) and raise HDL (good cholesterol) have been mentioned. This is the first one to show long term benefits over a period of 20 years.

Patients who received a combination drug-therapy had much lower levels of LDL and triglycerides as well as higher HDL and less fatty buildup in the carotid artery.

Loyola University Health System cardiologist Binh An P. Phan, MD, FACC was the lead author of this study and also presented it at the National Lipid Association 2012 Annual Scientific Sessions. At the beginning of the study, both groups had similar fatty buildup in their blood vessels and vascular age. After 20 years, the combination therapy group had a vascular age 10.2 years younger than that of the group taking a single statin medication.

The "vascular age" shows how old an individual's blood vessels appear to be based on risk factors and plaque buildup. It can either be lower or higher than an individual's chronological age. For example, in the combination therapy group the vascular age was 74, about 7 years older than the average chronological age. In contrast, the single medication group had a vascular age of 84, or 20 years older than their chronological age.

Phan and his colleagues also critiqued an older study, known as FATS (the Familial Atherosclerosis Treatment Study), that was carried out when lovastatin and other statins were still unproven. Since then, statins have become standard therapy to help achieve lower cholesterol. This study separated patients with extremely high cholesterol into 3 different categories: Lovastatin (Mevacor) plus colestipol groupColestipol plus niacin groupThe placebo groupAfter the initial phase, some patients agreed to continue on with an observational study that lasted 20 years.

During this observational study, one group received one statin and the other group received combination therapy. After 11 years, the combination therapy was changed slightly. By the end of the study, 43 patients in the combination therapy group were still being followed up, as well as 26 patients in the single medication group.

After the study finished, the authors found that the combination therapy group had an LDL level of 85 milligrams per deciliter, while the single medication group had an LDL level of 103 milligrams per deciliter. In addition, the combination therapy group also had higher levels of HDL and lower levels of triglycerides.

The investigators conducted an ultrasound exam to measure fatty build-up in the carotid artery, commonly known as CIMT (carotid intima-media thickness). The CIMT was 17 percent thicker in the single medication group compared to the combination therapy group.

In conclusion, the researchers found the vascular age of the single medication group was much higher than the other group.

Phan wrote:

"These findings are the first to illustrate the benefits of long-term intensive combination lipid, cholesterol therapy, for 20 years in patients with atherosclerotic disease."

Written by Kelly Fitzgerald


Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today Visit our cholesterol section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Kelly Fitzgerald. "Lowering Cholesterol - Long-term Multiple Drugs Effective." Medical News Today. MediLexicon, Intl., 29 Jun. 2012. Web.
5 Jul. 2012. APA

Please note: If no author information is provided, the source is cited instead.


'Lowering Cholesterol - Long-term Multiple Drugs Effective'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Friday, July 6, 2012

Gestational Diabetes Risk Associated With Antipsychotic Drugs During Pregnancy

Editor's Choice
Main Category: Pregnancy / Obstetrics
Also Included In: Diabetes;  Psychology / Psychiatry
Article Date: 03 Jul 2012 - 10:00 PDT Current ratings for:
Gestational Diabetes Risk Associated With Antipsychotic Drugs During Pregnancy
not yet ratednot yet rated
Women who take antipsychotic drugs during pregnancy are more likely to develop gestational diabetes, say researchers.

The study, conducted by Robert Bodén. M.D., Ph.D., of the Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, and Uppsala University, Uppsala, Sweden, and colleagues, is published in Archives of General Psychiatry.

Antipsychotic drugs are used to treat severe mental illnesses such as schizophrenia and bipolar disorder, "however, the evidence concerning use of antipsychotics during pregnancy is generally lacking or weak," say the researchers.

For the study, the team examined medical records of Swedish women who gave birth in Sweden between July 2005 and December 2009. Of the women examined, 357,696 had no prescriptions for antipsychotics, 169 women were prescribed the antipsychotics olanzapine and/or clozapine, and 338 were prescribed other antipsychotics.

The researchers said:

"Gestational diabetes was more than twice as common in mothers who used antipsychotics (seven mothers [4.1 percent] for those prescribed olanzapine and/or clozapine and 15 [4.4 percent] for those prescribed other antipsychotics) than in the total population of pregnant women (5,970 [1.7 percent])."

Although the team found that women were more likely to give birth to a small for gestational age (SGA) infant if they were using antipsychotics, the risk was no longer statistically significant after adjusting for maternal factors.

The researchers explained:

"In conclusion, maternal use of antipsychotics during pregnancy, regardless of the drug group, is associated with an increased risk of gestational diabetes. The increased risk of giving birth to an SGA infant observed among women treated with antipsychotics during pregnancy is probably an effect of the confounding factors, such as smoking."

In addition, results showed that exposure to olanzapine and/or clozapine did not increased the risks of being large for gestational age (LGA) for birth weight or birth length. However, the risks did increase for head circumference.

The researchers conclude: "Pregnant women treated with antipsychotics should be closely monitored for gestational diabetes and deviating fetal growth."

Written by Grace Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our pregnancy / obstetrics section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Grace Rattue. "Gestational Diabetes Risk Associated With Antipsychotic Drugs During Pregnancy." Medical News Today. MediLexicon, Intl., 3 Jul. 2012. Web.
5 Jul. 2012. APA

Please note: If no author information is provided, the source is cited instead.


'Gestational Diabetes Risk Associated With Antipsychotic Drugs During Pregnancy'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here